Value of Tomosynthesis for the Detection of Sacro-iliitis (TOMOS SI)
Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Sep 28, 2018
Trial Information
Current as of July 23, 2025
Unknown status
Keywords
ClinConnect Summary
Consecutive patients referred to CT for exploration of sacrollitis will be included and investigated with standard radiography, CT and tomosynthesis of SI joints.
Imaging examinations will be performed at day of enrollment as follow : X-ray and CT as standard management and tomosynthesis as additional evaluation. CT will be considered as the reference standard Sacroiliitis will be assessed in a centralized, blind and randomized retrospective reading of all imaging modalities by two independent radiologists.
Diagnostic performances and radiation doses of tomosynthesis will be compared to t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged 18 and over referred for suspected sacroiliitis.
- • Patients who have entered into their participation agreement by signing the informed consent form.
- • Patient affiliated to a social security scheme or beneficiary.
- Exclusion Criteria:
- • Pregnant or lactating women.
- • Vulnerable people according.
- • Major people placed under guardianship or curatorship.
About University Hospital, Montpellier
The University Hospital of Montpellier is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its commitment to patient-centered care, the hospital collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. By integrating clinical practice with education and research, the University Hospital of Montpellier aims to enhance health outcomes and contribute to the scientific community's understanding of complex medical conditions. Its robust infrastructure and expertise make it a pivotal player in the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montpellier, , France
Patients applied
Trial Officials
Catherine Cyteval, MD, PhD
Principal Investigator
Montpellier University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials